| β-blockers (n = 307) | Thiazide (n = 196) | CCBs (n = 322) | RAS (n = 55) | Others* (n = 338) | p value |
---|---|---|---|---|---|---|
Age (years) | Â | Â | Â | Â | Â | Â |
<50 | 85 (27.7) | 38 (19.4) | 74 (23.0) | 9 (16.4) | 58 (17.2) | <0.001 |
50–59 | 113 (36.8) | 62 (31.6) | 87 (27.0) | 22 (40.0) | 84 (24.9) |  |
60–69 | 59 (19.2) | 51 (26.0) | 70 (21.7) | 11 (20.0) | 77 (22.8) |  |
≥ 70 | 50 (16.3) | 45 (23.0) | 91 (28.3) | 13 (23.6) | 119 (35.2) |  |
Mean Age | 56.96 | 60.14 | 60.80 | 60.02 | 63.30 | <0.001 |
(SD) | (11.67) | (11.37) | (13.21) | (12.83) | (13.42) | Â |
(95% CI) | (55.651,58.27) | (58.54, 61.74) | (59.36, 62.25) | (56.55, 63.49) | (61.87, 64.74) | Â |
Gender (no./%) | Â | Â | Â | Â | Â | Â |
Female | 200 (65.1) | 124 (63.3) | 168 (52.2) | 33 (60.0) | 189 (55.9) | 0.008 |
Male | 107 (34.9) | 72 (36.7) | 154 (47.8) | 22 (40.0) | 149 (44.1) | Â |
Payment | Â | Â | Â | Â | Â | Â |
Fee-waivers | 107 (34.9) | 68 (34.7) | 107 (33.2) | 17 (30.9) | 96 (28.4) | 0.415 |
Payers | 200 (65.1) | 128 (65.3) | 215 (66.8) | 38 (69.1) | 242 (71.6) | Â |
District of residence | Â | Â | Â | Â | Â | Â |
Shatin | 85 (27.7) | 44 (22.4) | 84 (26.1) | 12 (21.8) | 135 (39.9) | <0.001 |
Taipo | 31 (10.1) | 13 (6.6) | 52 (16.1) | 5 (9.1) | 37 (10.9) | Â |
Northern | 161 (52.8) | 127 (64.8) | 169 (52.5) | 34 (61.8) | 134 (39.6) | Â |
Others | 30 (9.4) | 12 (6.1) | 17 (5.3) | 4 (7.3) | 32 (9.5) | Â |
Service type | Â | Â | Â | Â | Â | Â |
General | 264 (86.0) | 179 (91.3) | 288 (89.4) | 48 (87.3) | 275 (81.4) | <0.001 |
FMSC | 29 (9.4) | 7 (3.6) | 27 (8.4) | 4 (7.3) | 56 (16.6) | Â |
Staff clinic | 14 (4.6) | 10 (5.1) | 7 (2.2) | 3 (5.5) | 7 (2.1) | Â |
Glucose Profile | 5.42 | 5.48 | 5.46 | 5.41 | 5.60 | 0.786 |
(mean ± 95% CI) | (5.34, 5.51) | (5.38, 5.59) | (5.37, 5.54) | (5.20, 5.61) | (5.52, 5.68) |  |
Period from drug prescription to blood taking (weeks) | 7.43 | 7.00 | 7.79 | 6.71 | 8.00 | 0.054** |
Median (IQR) | (5.86, 10.00) | (5.18, 8.96) | (5.57, 10.32) | (5.00, 10.00) | (6.00, 12.00) | Â |